May 06, 2024

Pliant Therapeutics

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

April 23, 2024

Flare Therapeutics

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) As Chief Executive Officer

April 09, 2024

Seaport Therapeutics

Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines

April 09, 2024

Flare Therapeutics

Flare Therapeutics Presents Data At AACR 2024 Annual Meeting Characterizing PPARG-Derived Immune Cell Patterns in Urothelial Cancer Patients After Anti-PD1 Therapy

April 02, 2024

Tango Therapeutics

Tango Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635( C) (4)

Load More

Sign up for weekly portfolio news.